Learn about MSK’s Healthy Living, a lifestyle program for people with breast cancer, where diet, nutrition, exercise and integrative medicine come together to improve quality of life.

Discover the joys of crafting your very own DIY terrarium and transform your space into a green oasis! Whether this is your first time or you are a crafty botanical enthusiasts, this virtual workshop ...

En esta información se explica qué son el síndrome de liberación de citocinas y el síndrome de neurotoxicidad. También se describen las causas, los síntomas y los tratamientos comunes de cada enfermed ...

Learn about a new approach to helping reduce the risk of stomach and esophageal cancer coming back after surgery, thanks to a clinical trial with immunotherapy led by researchers at MSK.

For the first time, a targeted drug is showing promise at treating non-small cell lung cancer caused by a mutation called KRAS-G12D.

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation or chemotherapy.

MSK physician-scientists Dr. Viviane Tabar and Dr. Lorenz Studer have developed a treatment for Parkinson’s disease that involves creating nerve cells from embryonic stem cells and transplanting them ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo Oviedo-Mori survive — and thrive — with advanced lung cancer for 15 years.

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient’s own immune T cells and engineering them to recognize specific targets ...

Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood ...